Psychiatry ยท Medical Literature
Selective enhancement of cost sensitivity by methylphenidate in adult ADHD: a randomized placebo-controlled trial.
Abstract
Attention-deficit hyperactivity disorder (ADHD) is associated with impairments in real-life decisions, many involving balancing costs and benefits. Increasing dopamine and norepinephrine with stimulant medication improves decision-making in ADHD. However, it is unclear whether stimulant medication affects sensitivity to costs and/or benefits or alters the speed-accuracy tradeoff. Here, we applied the drift diffusion model (DDM) to assess how the stimulant medication methylphenidate (MPH) affects subprocesses of cost-benefit decision-making in ADHD. Sixty-one adult participants with ADHD and 63 healthy controls completed a cost-benefit decision-making task in a randomized double-blind placebo-controlled design. ADHD participants were tested once on and once off MPH. Control participants performed the task in two sessions without medication. The task entailed deciding whether to accept or reject a stimulus based on learned cost and benefit value associations. The effect of ADHD and medication on subprocesses of decision-making was disentangled by estimating task performance with DDM parameters drift rate, starting point bias, and decision threshold, representing evidence accumulation, a priori accept/reject bias, and the speed-accuracy tradeoff, respectively. Primary analyses used a modified intention-to-treat sample, including participants with main-phase data from both sessions. The DDM analysis identified impaired evidence accumulation combined with premature responding in participants with ADHD, indicated by reduced sensitivity to costs and benefits and narrower decision thresholds. MPH altered the cost-benefit balance by improving sensitivity to costs. Lastly, lower cost sensitivity was associated with greater symptom severity and higher prescribed dosage in ADHD. Methylphenidate alters cost-benefit decision-making in ADHD by increasing sensitivity to costs.
Clinical relevance
Adults with ADHD demonstrate clinically meaningful impairments in cost-benefit decision-making, a domain directly relevant to real-world functioning including financial, occupational, and social choices. This randomized, double-blind, placebo-controlled trial addresses a mechanistic gap by applying the drift diffusion model (DDM) to dissect the specific cognitive subprocesses through which methylphenidate (MPH) exerts its therapeutic effect on decision-making. Understanding the selective neurocognitive targets of stimulant medication is critical for optimizing treatment strategies and setting realistic expectations about which decisional deficits MPH will and will not remediate.
Key findings
1. Adults with ADHD (n=61) demonstrated reduced drift rates for both cost and benefit information compared to healthy controls (n=63), indicating globally impaired evidence accumulation during cost-benefit decision-making. 2. ADHD participants exhibited narrower decision thresholds than controls, reflecting a pattern of premature responding and a suboptimal speed-accuracy tradeoff, independent of medication status. 3. MPH produced a selective improvement in sensitivity to costs (drift rate for cost information) without significantly enhancing sensitivity to benefits, indicating a specific rather than global enhancement of evidence accumulation. 4. The cost-benefit balance was shifted by MPH through this selective cost-sensitization effect, altering the accept/reject decision profile in a directionally meaningful way. 5. Lower cost sensitivity at baseline was significantly associated with greater ADHD symptom severity, suggesting that decisional impairment tracks clinical burden. 6. Lower cost sensitivity was also associated with higher prescribed MPH dosage, indicating that real-world clinician dosing may partly reflect the severity of this neurocognitive deficit. NOTE: Specific effect sizes, confidence intervals, and p-values were not reported in the provided abstract; quantitative precision is therefore limited to the directional and qualitative findings described.
Practice implications
Clinicians should recognize that MPH in adult ADHD selectively improves sensitivity to costs in decision-making rather than conferring a broad enhancement of decisional cognition, meaning patients may remain relatively insensitive to potential benefits even when optimally medicated. When evaluating treatment response in adult ADHD, assessment of real-world cost-benefit decision-making (e.g., impulsive spending, risk-taking, effort avoidance) should be incorporated alongside symptom rating scales, as cost sensitivity correlates with symptom severity and prescribed dose. Patients with more severe ADHD symptoms and higher prescribed MPH doses may represent a subgroup with particularly impaired decisional cost processing, warranting targeted psychoeducation or adjunctive cognitive-behavioral strategies to address residual benefit-sensitivity deficits not corrected by stimulant medication alone.